Lena Rydberg Freese, DO
Internal Medicine · West Des Moines, IANPI 1124257019
Payments from drug & device makers
What this record shows
This record is dominated by travel and lodging: $1,151 of the $1,779 with a category attached, or 64.7%. Novo Nordisk accounts for 88.2% of it on its own, with 5 other manufacturers making up the rest. Reporting peaked in 2019 at $1,501 and has fallen 97.9% since, to $32 in 2025. Among internal medicine clinicians in IA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 15 payments — averaging $118.61 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- Novo Nordisk$2K
- AbbVie$99
- Medtronic$36
- Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$29
- Abbott$24
- Insulet Corporation$21
Across 154 payments — averaging $11,716 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Modernatx, Inc.$1.2M
- Pfizer$216K
- Astrazeneca UK Limited$196K
- AstraZeneca$124K
- Sanofi Pasteur Inc.$21K
What the payments were for
- Travel & lodging$1,15165%
- Food & beverage$56632%
- Education$623%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| Novo Nordisk | 5 | $1,570 |
| AbbVie | 4 | $99 |
| Medtronic | 2 | $36 |
| Salix Pharmaceuticals, A Division Of Bausch Health US, LLC | 2 | $29 |
| Abbott | 1 | $24 |
| Insulet Corporation | 1 | $21 |
How this compares
$1,779 in reported general payments places this provider in the 90th percentile of 583 internal medicine providers in Iowa.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| OzempicSemaglutide | 151 | $233,518 |
| MounjaroTirzepatide | 104 | $148,068 |
| EliquisApixaban | 104 | $85,591 |
| JanuviaSitagliptin Phosphate | 48 | $52,897 |
| XareltoRivaroxaban | 46 | $50,252 |
| RybelsusSemaglutide | 33 | $44,098 |
| Omnipod 5 Dexg7g6 Pods (Gen 5)Insulin Pump Cart,auto,bt,g6/7 | 34 | $43,415 |
| JardianceEmpagliflozin | 34 | $27,601 |
| NamzaricMemantine Hcl/Donepezil Hcl | 17 | $15,536 |
| MyrbetriqMirabegron | 13 | $9,251 |
| Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog | 13 | $9,203 |
| Breo ElliptaFluticasone/Vilanterol | 20 | $8,005 |
| Praluent PenAlirocumab | 12 | $5,730 |
| ShingrixVaricella-Zoster Ge/As01b/Pf | 22 | $4,863 |
| Lantus SolostarInsulin Glargine,hum.Rec.Anlog | 34 | $4,788 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Novo NordiskOzempic, Rybelsus | $1,570 | $277,616184 claims |
| AbbVieNamzaric, Synthroid | $99 | $18,07541 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 583 internal medicine providers in Iowa.
Other internal medicine in West Des Moines
- Jose AngelWest Des Moines$2K
- Kathleen JonesWest Des Moines$2K
- Mark JohnsonMason City$223K
- Mark CarlsonSioux City$174K
- Madalyn WalshIowa City$80K
- Alan KricsfeldCouncil Bluffs$49K
- Aziz HammoudIowa City$29K
- Matthew FryzekCouncil Bluffs$28K
- Diana Rabadi MararCouncil Bluffs$25K
- Isam MararCouncil Bluffs$23K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.